Market Newsdesk

VANCOUVER, British Columbia, Dec. 02, 2020 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, is pleased to provide an introduction to Dr. Alexander MacGregor, a key scientific advisor to the Company.

Pure Extracts and Dr. MacGregor are collaborating on the development of CBD infused mushroom wellness products and are researching the optimum extraction methodologies for psilocybin in order to prepare the Company to enter the psychedelic mushroom extraction space.

Dr. MacGregor is the Dean of Faculty, distinguished Professor of Biopharmaceutics and current President of the Toronto Institute of Pharmaceutical Technology (TIPT^®) – North America’s premier post-graduate institute of pharmaceutical sciences, technology and research. He is also the CEO of TIPT’s parent company, Transpharm Canada Inc., which has a Health Canada Drug Establishment License, a Cannabis Drug License and a Dealer’s License issued under the Controlled Drugs and Substances Act (CDSA). Transpharm Canada conducts cannabis testing, clinical trials, drug development and is licensed to possess psychedelic drug compounds.

Dr. MacGregor is recognized as a pharmaceutical science inventor and expert in pharmaceutical technology and novel drug delivery systems. He is a recipient of several global patents in the field of medical treatments and pharmaceutical drug delivery technologies most notably from Canada, US, Australia, Europe, Latin America, China, India and Japan. His inventions have led to groundbreaking therapeutic drugs for the treatment of cancer, management of diabetes, systemic infections, and post-operative pain.

An expert in translating pharmaceutical knowledge into sustainable businesses, Dr. MacGregor was a consultant to multi-national pharmaceutical companies such as GlaxoSmithKline, Valeant, Teva, Patheon, Sun Pharma and Beijing Double-Crane Pharma. He was appointed by the Government of China as an International Advisor in the field of pharmaceutical technology and research through a nomination proffered by the City of Beijing and Beijing Double-Crane Pharmaceutical Co. (China’s third largest pharmaceutical company).

He is the author and co-author of several articles and manuscripts in the field of pharmaceutical science and technology, a founding member and Chair of the Canadian Association of Pharmaceutical Technologists (CapTech) and the founding member and past-Chair of the Toronto Pharmaceutical Ethics Committee for research in humans. He is a member of several scientific associations such as the prestigious Control Release Society (CRS), Canadian Society of Pharmaceutical Sciences (CSPS) and the American Association of Pharmaceutical Sciences (AAPS).

Dr. MacGregor received an honours degree (Magna Cum Laude-BSc) in Medical Biochemistry and Doctor of Philosophy (Ph.D.) in Clinical Pharmacology from the University of Wales and the Royal Post-Graduate Medical School London, UK.

About Pure Extracts

(
CSE: PULL
)
(XFRA: A2QJAJ)

The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020. Find out more at https://pureextractscorp.com/.

For further information please contact Empire Communications Group at (604) 343-2724.

ON BEHALF OF THE BOARD

“

Ben Nikolaevsky

”

Ben Nikolaevsky
CEO and Director

The CSE has neither approved nor disapproved the contents of this press release.

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations.

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) — DoubleVerify (“DV”), a leading software platform for digital media measurement, data and analytics, today announced the launch of the DV Publisher Suite, providing the measurement, insights and tools digital publishers need to improve ad delivery, assess inventory quality and maximize yield. 

For publishers, generating revenue has never been more complex. Today’s demand-side landscape consists of thousands of potential buyers, each with their own unique requirements, transacting through dozens of intermediary buying platforms. Each partner generates an incredible volume of quality, performance and delivery data related to a publisher’s inventory. 

This complexity creates a host of challenges, with publishers having to manually aggregate, normalize, and reconcile the many data sets related to inventory performance and revenue —  an error-prone, resource intensive process. There is also a lack of transparency into the impact of media quality data, impeding publishers’ ability to meet advertiser KPIs and achieve full inventory potential. In addition, publishers are often placed in a reactive position, leading to lost revenue and friction with buyers when performance issues are not uncovered in a timely manner.

The DV Publisher Suite addresses these challenges — and was designed to reduce the administrative overhead required to manage third-party revenue and measurement data, empower publishers through actionable inventory insights, and automate proactive optimization with tools that identify and resolve delivery issues. These functions are combined across all of a publisher’s inventory — whether direct-sold or programmatic, empowering publishers to streamline operations and maximize revenue. 

“Publishers deserve to be compensated for the quality content and programming they create, and audiences they garner,” said Matt McLaughlin, COO of DoubleVerify. “The DV Publisher Suite provides the measurement, insights and tools to improve ad delivery, enhance inventory quality and drive performance — all with the goal of boosting yield.”

The DV Publisher Suite offers: 

• Unified Analytics — Aggregate all data sources and revenue channels to make informed decisions through robust reporting and dashboards.
• Campaign Delivery Insights — Supercharge operations and streamline billing with visual campaign performance monitoring on pacing, discrepancies and more.
• Media Quality Insights and Automation — Generate new revenue by discovering high-performing inventory based on DV fraud, viewability and brand safety data.
• Industry Benchmarks — Get actionable insights for yield optimization by comparing inventory performance with industry benchmarks.
• Video Delivery Automation — Speed up load times, avoid missed impressions, improve user experience and maximize yield from valuable video inventory.

At launch, publishers using the DV Publisher Suite include Hearst, Meredith, Healthline, TechTarget, Univision, Comcast, Mashable, Remedy Health Media, among others. 

“DV Publisher Suite will provide granular, real-time brand safety insights across all of our inventory beyond the scope of keywords that an advertiser flags,” said Tara Nanda, Senior Manager, Business Intelligence of ESSENCE. “We are excited to use these tools to maximize inventory value across display and video and ensure we are meeting advertiser expectations.”

To learn more about DV Publisher Suite, email [email protected]. 

About
DoubleVerify

DoubleVerify is a leading software platform for digital media measurement, data and analytics. DV’s mission is to be the definitive source of transparency and data-driven insights into the quality and effectiveness of digital advertising for the world’s largest brands, publishers and digital ad platforms. DV’s technology platform provides advertisers with consistent and unbiased data and analytics that can be used to optimize the quality and return on digital ad investments. Since 2008, DV has helped hundreds of Fortune 500 companies gain the most from their media spend by delivering best in class solutions across the digital advertising ecosystem, helping to build a better industry. Learn more at www.doubleverify.com.

Contact: [email protected]

AUSTIN, Texas, Dec. 02, 2020 (GLOBE NEWSWIRE) — HotSchedules, the leading provider of end-to-end, best-in-class technology and services for the restaurant and hospitality industries, announced today the company will be operating under a unified global brand, Fourth, effective immediately. The new brand represents a global portfolio of customer-focused solutions and services including inventory, task and labor management, analytics, HR and payroll services. As Fourth continues to create solutions for the industry’s most complex challenges, they will officially extend their widely adopted workforce management offerings to the retail industry. 

As a natural extension to its hospitality roots, Fourth is excited to announce its entrance into the retail sector. With the retail industry facing similar work/life balance and labor management challenges, Fourth will continue to expand its workforce management platform, HR and payroll services to empower retailers to win with talent, operate effortlessly, and deliver on their unique brand promise. With Fourth technology streamlining many cumbersome operations for managers and employees alike, retailers will be better positioned to serve shoppers for a heightened guest experience, while also maximizing productivity and driving revenue. 

“With more than two decades of leading labor management in the hospitality space, we are proud to expand our offerings under the global brand, Fourth, and further provide our customers with proven solutions to solve rapidly-evolving challenges across the workplace,” said Clinton Anderson, CEO of Fourth. “Sustaining our focus on the hospitality industry, we will solve similar workforce management challenges faced by retail operators. This expansion marks a significant milestone for our company as we advance strategically and offer our solutions and services across a growing number of industries.”

In 1999, HotSchedules launched a complete labor management tool with a mission to solve one of the hospitality industry’s most complex problems of keeping teams connected. Through the years, businesses have relied on HotSchedules to simplify scheduling, control labor costs, and provide a seamless communication experience from the hourly team member to the CEO. Since then, the company has diversified its solutions and services to meet current operator needs easily and efficiently.  Under the rebrand, HotSchedules will continue to be the flagship workforce management solution for Fourth in the United States.

HotSchedules and Fourth collectively represent 40 years in hospitality, serving over 7,000 customers and 120,000 locations. To learn more about the company’s solutions and services for hospitality and retail, please visit https://www.fourth.com/.

About Fourth Enterprises

Fourth Enterprises LLC, parent company of HotSchedules and Fourth, provides end-to-end, best-in-class technology and services for the restaurant, hospitality and retail industries. Their inventory and workforce management solutions, coupled with the industry’s most complete data and analytics suite, give operators the actionable insights they need to control costs, scale profitability, improve employee engagement, and maintain compliance. Headquartered in Austin, Texas, Fourth Enterprises serves more than 7,000 customers across 120,000 locations globally. For more information, please visit www.fourth.com.

Media Contact:
Sara Davis/Madison McGillicuddy
ICR for Fourth
646.677.1826
[email protected]

CALGARY, Alberta, Dec. 02, 2020 (GLOBE NEWSWIRE) — Canadian North is pleased to announce the appointment of Matieu Plamondon to the role of Vice-President, Charters and Business Development, effective January 4, 2021. Matieu will be based in Calgary, Alberta and lead Canadian North’s industry-leading charter operations.

Matieu joins Canadian North with widely-respected industry experience, having been named to the Wings Magazine Top 20 under 40 list in 2017. He has most recently served as Chief Operating Officer for Flyht Aerospace Solutions Ltd., a Calgary-based aerospace technology company. He has also served as Vice-President, Operations & Customer Fulfillment and Senior Operations Manager for Flyht.

Prior to joining Flyht, Matieu worked for Canadian North’s legacy airline, First Air, for eight years, advancing to the role of Director, Operational Control Centre. He has also worked in management positions for Navtech Systems Inc. and Pem Air Ltd. /Trillium Air Inc., has an MMBA from McGill University, has trained as an Aircraft Maintenance Engineer and is a licensed pilot.

Canadian North has earned its reputation for providing safe, reliable, flexible and cost-effective ‘Fly Anywhere’ charter flight services to major resource sector clients, government agencies, sports teams, tour operators, cruise lines and other large groups. It operates thousands of flights on behalf of its clients each year throughout Canada, the United States and beyond, with its own dedicated charter bases and maintenance facilities in Calgary and Edmonton and the ability to operate from a huge range of urban and remote airports and aerodromes. Canadian North also provides essential passenger and cargo services to communities in Nunavut, Nunavik and the Northwest Territories from its southern gateways of Ottawa, Montréal and Edmonton, with major operational hubs in Iqaluit, Yellowknife and Cambridge Bay.

“Canadian North is extremely proud of the safe and innovative charter services we provide to an incredible array of Canadian businesses and organizations,” said Chris Avery, President and CEO of Canadian North. “We look forward to welcoming Matieu to this new role, where he will lead our Charters team in providing exceptional service and care to all of our customers while continuing to grow this important part of our company.”

About Canadian North:

Canadian North is a 100% Inuit-owned airline that connects people and delivers essential goods throughout Canada’s North – safely, reliably and always with friendly and helpful customer service. It operates to 26 destinations within the Northwest Territories, Nunavik and Nunavut, from its southern gateways of Ottawa, Montréal and Edmonton, with a versatile fleet of Boeing 737 and ATR 42 aircraft. Canadian North is also the premier charter services provider for large resource sector clients requiring dependable, efficient and economical fly-in/fly-out air service and it operates flights across North America and beyond for sports teams, cruise lines, tour operators and other large groups. Canadian North is wholly-owned by Makivik Corporation and Inuvialuit Development Corporation.

For more information please contact:

Kevin Kablutsiak
Senior Director, Marketing and Communications
Canadian North
Contact: Cell 613-282-2440 | [email protected]
Websites: charters.canadiannorth.com | www.canadiannorth.com

ORLANDO, Fla., Dec. 02, 2020 (GLOBE NEWSWIRE) — ACME AtronOmatic, LLC, the makers of the popular MyRadar weather app, announced today that it has partnered with Suunto to bring their advanced weather data and forecasting technologies to the Suunto Sport Watch collection. 

MyRadar has a number of weather and environmental related features that make it an ideal companion for the outdoor enthusiast, and the Suunto 7 complements these features in a form factor perfectly suited for the casual wearer or an active lifestyle.

Some key features extended to the Wear app include real-time radar view for the wearer’s location and a handy summary view for the current weather conditions, among others. Wrist-accessible data includes current temperature, max min temperatures, precipitation probability, wind speed and wind direction, a colorful temperature graph showing cooler or warmer temperatures as they occur throughout the day, an hourly forecast with the temperature and weather conditions for 13 hours, and the 5 day forecast with a colorful display that indicates temperature changes and other related information.

The user experience is further enhanced with the integration of MyRadar’s patent-pending, industry-leading nowcasting service which provides hyper-local rain and precipitation alerts with down-to-the-minute accuracy.

“We are incredibly excited to collaborate with the excellent team at Suunto,” said Andy Green, ACME CEO.  “Suunto has a long history as a leader in the Sport Watch industry, and we are thrilled that they chose to integrate our industry leading weather technology into their advanced lineup devices. The meshing of our technology with the robust capabilities of the Suunto devices will allow us together to create further innovations for future applications and services.” 

“Suunto is about equipping people in their outdoor lifestyle. To know what to expect when starting the hike in wilderness, requires understanding of several aspects. One being the local weather. The MyRadar give this for Suunto 7 owners this knowledge in perfect package. This co-operation illustrates the power of modern wearables and tools that leaders on their own field such as MyRadar in weather can provide for outdoor enthusiasts,” said Janne Kallio Head of Partner Products, Suunto.  

Suunto 7 is latest watch published by Suunto in January 2020. Suunto 7 combines the smart watch features powered by Google Wear OS and Suunto outdoor sports expertise.

About 
MyRadar
: MyRadar is a free weather and environmental information app for iOS, Android, Windows and Xbox.  First launched on the app store in 2008, the app has been downloaded over 50 million times, and has over 13 million monthly active users.  MyRadar has been keeping the world informed of severe weather, tropical storms, earthquakes, wildfires and more for over 10 years.  ACME AtronOmatic, LLC, the makers of MyRadar, has development offices in Portland, Oregon, and in Orlando, Florida.  The app is available on the iOS App Store, Google Play, and the Windows Store.  MyRadar is available online at youtube.com/myradar, twitter.com/myradarwx, facebook.com/myradar, and instagram.com/myradar

About 
Suunto: We stand for adventure. Pioneering exploration has been in our DNA since 1936, when Finnish orienteer Tuomas Vohlonen set out to create a more accurate compass, and subsequently invented a new method for manufacturing liquid‐filled compasses. Today Suunto is at the forefront of design and innovation for sports watches, dive computers and instruments used by adventurers all over the globe. We are proud that Suunto products can take a beating, but are also designed with an everyday aesthetic that reflects our Nordic identity. Suunto’s headquarters and factory are still in Finland. We are part of Amer Sports along with sister brands Salomon, Arc’teryx, Peak Performance, Atomic, Wilson and Precor.

Contact: 
Michelle Kafka
[email protected]

• New-generation Airfast RF Multi-Chip Modules (MCMs) extend frequency coverage to 4.0 GHz, leveraging the performance of NXP’s latest LDMOS technology and integration design techniques
• Higher output power than the previous generation supports the deployment of more powerful 5G mMIMO radios to cover larger urban areas
• Increased efficiency of up to 45% at 2.6 GHz helps reduce the overall electricity consumption of the 5G network

EINDHOVEN, The Netherlands, Dec. 02, 2020 (GLOBE NEWSWIRE) — NXP Semiconductors N.V. (NASDAQ: NXPI) today announced the availability of its 2^nd generation of comprehensive Airfast RF power Multi-Chip Modules (MCMs) designed to support the evolution of 5G mMIMO active antenna system requirements for cellular base stations. Focused on accelerating the coverage of 5G, the new all-in-one power amplifier module family is based on NXP’s latest LDMOS technology that offers higher output power, extended frequency coverage, and higher efficiency—all within the same footprint as NXP’s previous generation of MCMs.

The new AFSC5G26E38 Airfast module is a prime example of the increased performance delivered in the 2nd generation MCM family. The device delivers 20% more output power compared to the previous generation, addressing the need for broader 5G coverage per base station tower, without increasing the radio unit size. It also features a power-added efficiency of 45%, 4 points higher than the previous generation for an overall reduction in the 5G network electricity consumption. Highlighting the performance of NXP’s latest LDMOS generation in high frequencies, the new AFSC5G40E38 addresses the 5G C-band from 3.7 to 4.0 GHz and has recently been selected by NEC Rakuten Mobile in Japan.

“NXP’s latest multi-chip modules provide an efficiency boost resulting from the latest enhancements to LDMOS and enhanced integration,” said Paul Hart, Executive Vice President and General Manager of NXP’s Radio Power. “Our aggressive drive for integration brings more features into each module, which means fewer components for our customers to source, assemble and test. The result is a higher power yet more cost-effective, compact design. This translates into faster time to market for our customers and mobile network operators who are tackling the need for 5G expansion.”

A
Comprehensive
Multi-Chip Module
Portfolio
For
5G Expansion

NXP’s RF power Multi-Chip Modules include LDMOS ICs, paired with an integrated Doherty splitter and combiner and a 50-ohm in/out matching. This high level of integration removes RF complexities and eliminates multiple prototype passes, while the reduction of component count helps improve yields and decrease qualification cycle time. The 2^nd generation complements the initial series released last year, extending the frequency and power levels. Both generations share the same pin-out format to enable RF designers to quickly scale from one design to another, reducing overall development time.

The 2^nd generation of Airfast MCMs is comprised of 10 new devices covering 5G frequency bands from 2.3 to 4.0 GHz, from 37 to 39 dBm average output power. The devices are qualified now and will be supported by NXP’s new RF Circuit Collection, a digital library of RF power reference circuits.

NXP’s 5G Access Edge Portfolio

From antenna-to-processor, NXP offers a robust portfolio of technologies for powering the 5G Access Edge that delivers best-of-class performance and security for infrastructure, industrial, and automotive applications. This includes the company’s Airfast family of RF power solutions and its Layerscape family of programmable baseband processors for wireless data links, fixed wireless access, and small cell devices. To learn more, visit nxp.com/5G.

About NXP Semiconductors

NXP Semiconductors N.V. enables secure connections for a smarter world, advancing solutions that make lives easier, better, and safer. As the world leader in secure connectivity solutions for embedded applications, NXP is driving innovation in the automotive, industrial & IoT, mobile, and communication infrastructure markets. Built on more than 60 years of combined experience and expertise, the company has approximately 29,000 employees in more than 30 countries and posted revenue of $8.88 billion in 2019. Find out more at www.nxp.com.

NXP, Airfast and the NXP logo are trademarks of NXP B.V. All other product or service names are the property of their respective owners. All rights reserved. © 2020 NXP B.V.

For more information, please contact:

Americas & Europe		Greater China / Asia
Jason Deal		Ming Yue
Tel: +44 7715228414		Tel: +86 21 2205 2690
Email: [email protected]		Email: [email protected]

NXP-Comms
NXP-Corp

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/32fdb131-2a67-4c00-8d57-67fa75db111f

–Singer Michael Bublè lends a hand on Dec. 2 on Instagram by asking the public for support—

–Nurses
from SMYS’s 640,000-strong Facebook community ask for food, diapers and basic toiletries above toys, illustrating the dire situation they find themselves in this holiday season–

ENCINO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) —

WHAT:	“Operation: Reindeer Games” is a national annual holiday fundraiser that brings holiday gifts – and this year even the basics like food, diapers and toiletries– to nurses and their families in need. Now in its sixth year, the fundraiser is a partnership between Show Me Your Stethoscope (SMYS) Foundation, HOLLIBLU and several other organizations.
	This year’s requests from nurses for help through the “Operation: Reindeer Games” fundraiser are startling. Instead of toys, the fundraiser is overwhelmed with requests for food, diapers, toiletries, sheets and other basic necessities, further highlighting the significant toll the COVID-19 pandemic is having on the nursing community nationwide.   This year the requests for help have been so overwhelming that the Foundation is afraid they will have to turn people away for the very first time.  “Operation: Reindeer Games” provides a wonderful opportunity to give back to frontline workers who have given so much during 2020.
WHEN:	Wednesday, Dec. 2, 2020
	Singer Michael Bublè will lend a hand on Dec. 2 on Instagram to ask his millions of followers and the public for help raising enough money to meet as many of these thousands of requests as possible.  Mr. Bublè is a personal friend of HOLLIBLU CEO Cara Lunsford. He is a huge supporter of the medical community and has a long history of donating time and money to several hospitals and organizations. He and his family are extremely grateful to the nurses who have cared for their loved ones and touched their lives over the years.
	The “Operation: Reindeer Games” fundraiser will accept financial contributions up until mid-Dec.
WHERE:	Michael Bublè’s Instagram post via SMYS Instagram– https://www.instagram.com/p/CIRbYTEhjiC/
	Donation site – www.smysofficial.org/donate
INTERVIEW
OPP’s:	Cara Lunsford, RN – founder and CEO of HOLLIBLU
	Janie Harvey Garner, RN – founder of Show Me Your Stethoscope (SMYS) Foundation
	Nursing Families – to interview a local nurse who has applied for holiday assistance, please contact us via the Press Contacts section of this Media Alert below.
WHY:	Applications for help no longer ask for toys and gifts this holiday season, but basic living necessities. Brought on by 2020’s COVID-19 pandemic and natural disasters, nurses are experiencing deaths, widespread unemployment and/or pay cuts, food insecurity, homelessness and dozens of other tragedies that can be lessened by public donations.
MORE ON
HOLLIBLU:	HOLLIBLU is an exclusive community and app designed for nurses and created by nurses. It helps nurses connect, organize their professional life, restore their passion for nursing, and empower themselves to thrive. HOLLIBLU was founded by Cara Lunsford, RN based on a patient story that had a huge impact on her.  HOLLIBLU believes that every nurse has a story that stays with them throughout their life, a special moment with a patient or their family member. HOLLIBLU comes from the Holly Blue butterfly and is a sign of transformation, and a symbol of acceptance, honor and great energy. www.holliblu.com
MORE ON
SMYS:	Show Me Your Stethoscope (SMYS) Foundation is a not-for-profit organization that has been helping nurses for the past six years and has grown to a Facebook community of more than 640,000 members.  From helping nurses get scholarships to helping feed their families during the holidays, SMYS continues to show up for nurses in ways that no other organization has ever done. The community is continuously engaged and working tirelessly to promote safe staffing ratios along with other policy changes that will improve work conditions and patient safety.  www.smysofficial.org and www.facebook.com/showmeyourstethoscopepage/

PRESS
CONTACTS:	Stacey Doss
	SDDPR for HOLLIBLU
	[email protected]
	949-285-2362

OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has entered into an exclusive distribution agreement with RIKEN Genesis Co., Ltd, a subsidiary of The Sysmex Corporation (Sysmex), in Japan.

Under the agreement, RIKEN Genesis will exclusively distribute the T-SPOT Discovery SARS-CoV-2 kit (Research Use Only), developed by Oxford Immunotec for the detection and measurement of SARS-CoV-2 specific T cells, which may offer new insight into immunity to SARS-CoV-2 infection.

Based on the company’s T-SPOT technology, the only globally approved ELISPOT currently used clinically for the diagnosis of Tuberculosis infection; the T-SPOT Discovery SARS-CoV-2 kit is already available for research use across Europe and the USA. Trial data recently released by Public Health England¹ using the T-SPOT Discovery SARS-CoV-2 kit suggests that individuals with SARS-CoV-2 specific T cells but without detectible antibodies (serology) may be protected from infection.

Sysmex are committed to the establishment of diagnosis/treatment methods for COVID-19 and already offer PCR tests, antigen tests, and antibody tests. Following a successful trial of the T-SPOT Discovery SARS-CoV-2 kit in Japan, Sysmex believe offering a T cell response kit will form an important adjunct to their current range of tests for COVID-19.

Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec, said “We’ve been working with RIKEN Genesis for almost ten years now in Japan and we are delighted to deepen our partnership with this distribution arrangement for our research use SARS-CoV-2 T cell test. RIKEN’s strong channel to research customers in Japan will help broaden usage of our T-SPOT Discovery SARS-CoV-2 kit, which we believe will be able to make a significant contribution in informing how we can better manage the ongoing pandemic.”

Dr. Naoto Kondo, President and CEO of RIKEN Genesis, said “We are excited to start handling T-SPOT Discovery SARS-CoV-2 kit in Japan. We have provided the T-SPOT technology to Japan market in strong collaboration with Oxford Immunotec. We hope this kit will contribute to research support and drug development for COVID19, especially vaccine development.”

T-SPOT Discovery SARS-CoV-2 is for research use only, not for use in diagnostic procedures
.

Not all products are available in all
regions;
please contact us for information on availability in any specific country
.

For further information on T-SPOT Discovery SARS-CoV-2 visit: https://www.tspotdiscovery.com.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company. We bring energy and invention to a world in need of diagnostic truth. We are uniquely placed as the only company in the world offering regulated ELISPOT assays for T cell measurement, with approval around the globe. Our leading product, the T-SPOT^®.TB test, is used for diagnosing infection with Tuberculosis, the world’s largest cause of death from infectious disease. The Company is an experienced manufacturer of IVD tests, operating under a fully audited Quality Management System, ensuring rigorous batch control. The company has manufactured in excess of 20 million clinical T cell tests for TB infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.

About
RIKEN Genesis

Established in October 2007, RIKEN Genesis (a subsidiary of The Sysmex Corporation) provides products for genetic testing based on cutting-edge gene analysis technology and laboratory assay services with the mission of realizing precision medicine using genomic science and molecular diagnostic technology joined the Sysmex Group in June 2016 for the practical application of genomic medicine. RIKEN Genesis provides highly reliable tests based on international quality standards in laboratories that have obtained CAP certification / CLIA certification and ISO 15189 certification, and has a track record in clinical sequence, drug discovery research support, and clinical research support. Additional information can be found at the RIKEN Genesis website www.rikengenesis.jp or at The Sysmex Corporation site https://www.sysmex.co.jp/en/.

About T-SPOT

Discovery

SARS-CoV-2

Oxford Immunotec has been developing and strengthening its expertise in T cell measurement for over 15 years since the introduction of its T-SPOT technology in the field of TB diagnostics. In that time, we have taken the classic ELISPOT technique and developed it into the world leading proprietary T-SPOT technology platform we now use to measure T cell immune responses, improving performance, standardising results, and streamlining the workflow. This high performance is ensured by our regularly audited manufacturing facility operating to our rigorous quality management system. The T-SPOT.TB test, an in vitro diagnostic (IVD) test using the T-SPOT technology platform, has been granted regulatory approval for clinical diagnostic use in over 50 countries, including US, EU, Japan and China. The research use-only T-SPOT Discovery SARS-CoV-2 assay uses this same T-SPOT technology to allow SARS-CoV-2-specific T cells to be detected and enumerated. The optimized antigen mix used in the test is based on SARS-CoV-2 structural proteins and allows the maximum breadth of the immune response to be measured. The Companies single antigen-per-well approach allows specific information about the immune response to different SARS-CoV-2 antigens to be gathered in parallel. Sample processing can be centralised whilst still enabling testing on fresh (rather than frozen) blood, using the Company’s T-Cell Xtend^® reagent (32 h room temperature (RT) sample stability) or T-Cell Select™ reagent (54 h RT sample stability – automated processing). The T-Cell Select reagent kit also allows for automation and therefore accommodates variations in scale – automation solutions are available for low, medium and high throughput settings.

T-SPOT, the Oxford Immunotec logo, T-Cell Xtend, T-Cell Select and T-SPOT Discovery are trademarks of Oxford Immunotec Limited.

Forward-Looking Statements

Certain statements in this press release constitute forward-looking statements within the meaning of applicable U.S. and U.K. laws and regulations, including under the U.S. Private Securities Litigation Reform Act of 1995. Any statements contained herein which do not describe historical or current facts, including beliefs the Company’s distribution arrangement with RIKEN Genesis to market the T-SPOT^® Discovery SARS-CoV-2 kit for the measurement of the T cell immune response to SARS-CoV-2 infection in Japan will provide data that provides new insights into immunity to COVID-19, including the belief that measuring T cells, in conjunction with other tests, may overcome limitations with the measurement of antibody-mediated immunity as well as other expected benefits of the T-SPOT Discovery SARS-CoV-2 test kit, including that the T cell assay may support efforts to combat COVID-19 and beliefs that the distribution arrangement will yield important information constitute forward-looking statements. Any forward-looking statements are based on our management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the possibility that the distribution arrangement will not yield the expected benefits in a timely manner or at all, or that the results of the initial data analyses will not contribute to the study or assisting in COVID-19 efforts as expected; the Company’s Discovery line of testing might not be a successful or timely tool in combatting COVID-19, the risk that further research data from the Discovery test kit will not produce results that support its clinical use, the likelihood that the Company will be able to partner with a third party to make a testing device clinically available and the possibility that, even if ultimately made commercially available, the testing kit will not be efficacious in testing for or combatting COVID-19, as well as those other risks and uncertainties described in Oxford Immunotec’s filings with the U.S. Securities and Exchange Commission (the “Commission”), including the Company’s Annual Report on Form 10-K for the year-ended December 31, 2019 and its Quarterly Report on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020 and in any other reports it files with the Commission, including any other Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Oxford Immunotec’s filings with the Commission are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the Commission’s website, www.sec.gov.

Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. Investors should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. Oxford Immunotec does not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

For Investor Inquiries:

Matt McLaughlin
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
[email protected]

1 To view the PHE publication visit: https://www.medrxiv.org/content/10.1101/2020.11.02.20222778v1

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) — Grafana Labs, the composable observability and operational dashboarding company, today announced it has been inducted into the JPMorgan Chase Hall of Innovation. Each year, the JPMorgan Chase Hall of Innovation award recognizes select emerging technology vendors for their innovation, business value and disruptive nature.

“It is an honor to receive this recognition from JPMorgan Chase,” said Raj Dutt, Co-founder and CEO of Grafana Labs. “Nearly two years ago, JPMorgan Chase took a chance on us when we were barely 50 people and pushed us hard in a way that’s been a true win-win – helping us develop better software. They continued to push us on a path to evolve our vendor and database-neutral technology to support their own observability journey.”

The award was presented to Grafana Labs at the 12th Annual J.P. Morgan Technology Innovation Symposium. Grafana Labs received the award for driving innovative data strategy and generating business value at JPMorgan Chase.

“Grafana Labs has transcended a typical vendor relationship into a true collaboration. We are excited to recognize them in the JPMorgan Chase Hall of Innovation. They have embraced the bank’s complexity and helped us toward better observability, continually hearing and addressing our product enhancement requests. We have been able to enhance our application and infrastructure uptime with Grafana Labs, resulting in stronger business performance,” said George Sherman, Global Technology Infrastructure CIO, JPMorgan Chase. “My team and I look forward to continuing to work with Grafana Labs.”

Helpful Links

• 
  Grafana Website
  
• 
  Grafana Blog
  
• 
  Grafana on Twitter
  
• 
  Grafana on LinkedIn
  
• 
  Grafana on GitHub
  
  

About JPMorgan Chase & Co.

JPMorgan Chase & Co. (NYSE: JPM) is a leading global financial services firm with assets of $3.2 trillion and operations worldwide. The firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. A component of the Dow Jones Industrial Average, JPMorgan Chase & Co. serves millions of consumers in the United States and many of the world’s most prominent corporate, institutional and government clients under its J.P. Morgan and Chase brands. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.

About Grafana Labs

Grafana Labs supports organizations’ monitoring, visualization and observability goals through an open and composable platform built around Grafana, the open source software for beautiful monitoring and metric analytics and visualization. There are now more than 550,000 active installations of Grafana, and the instantly recognizable dashboards have become ubiquitous. Grafana Labs’ commercial products include Grafana Enterprise, with key features and support for large organizations, and Grafana Cloud, a managed Grafana-based stack that includes Prometheus and Graphite (for metrics) and Loki (for logs). Today, more than 1,000 customers—including Bloomberg, eBay, PayPal, and Sony—turn to Grafana Labs to help bring their data together, all through software that is vendor-neutral. Grafana Labs is backed by leading investors Lightspeed Venture Partners and Lead Edge Capital. Follow Grafana on Twitter at @grafana or visit www.grafana.com.

Media Contacts

Grafana Labs
Cathy Wright
Offleash PR
[email protected]
650-678-1905

JPMorgan Chase
Jennifer Lavoie
[email protected]
212.622.7068

Denver, CO, Dec. 02, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Pure Harvest Corporate Group, Inc. (OTCQB: PHCG), an emerging cannabis and hemp-CBD holding company, is pleased to announce that it has added David Chessler and his family office of Chessler Holdings as a strategic investment group. In addition to a significant capital investment in the Company, Mr. Chessler will also assist Pure Harvest’s CEO Matt Gregarek in strategic partnerships and acquisitions, deal structuring and future capital raises.  

Mr. Chessler is a dynamic and innovative leader with creative investing skills and has a history of entrepreneurship, turn-around successes and value-added investment in small to mid-cap companies. He began his career as an entrepreneur in 1994, founding ParView, one of the very first telematics companies providing remote monitoring and GPS-based asset tracking, and which resulted in a successful exit, selling to Ingersoll-Rand. Since leaving ParView in 2002, Mr. Chessler has invested in a wide variety of industries, ranging from technology to connected kiosks to media and content delivery. Mr. Chessler currently sits on over a dozen board of directors and serves as the managing director of Jordyn Holdings, Chessler Holdings, and Great White Shark Opportunity Fund specializing in growth capital investments, asset-based lending and distressed assets. 

“I could not be more pleased to add David Chessler to Pure Harvest,” stated Matthew Gregarek, CEO, Pure Harvest Corporate Group. “He’s truly the most creative deal maker I know.  David brings a unique set of skills to Pure Harvest that will help us in our next phase of growth.”

“It is a privilege and opportunity to join the team at Pure Harvest,” stated David Chessler. “I am very discerning as to where I place my time and capital. Pure Harvest and Matt Gregarek provide both the management experience and the tremendous potential in quickly going vertical that is requisite for me.”

“Most importantly, I am eager to assist in the launch of a game changing, soon to be released, product that is guaranteed to disrupt the entire CBD industry.  The product is patent pending and has a legal opinion that gives the company the ability to distribute the product nationwide,” added Chessler.

About Pure Harvest Corporate Group

The Pure Harvest Corporate Group, Inc. (OTCQB: PHCG) is a publicly traded holding company operating in various segments of the cannabis and hemp-CBD industries. The PHCG team is committed to formulating, manufacturing, and distributing high-quality cannabis and hemp-CBD consumer products in markets where it is legal to do so. The Company has developed numerous retail brands and product lines for that are currently available for purchase in select markets. Pure Harvest intends to grow its cannabis and hemp-CBD operations and expand globally as the laws regarding cannabis and hemp-CBD are reviewed and rewritten to repeal their prohibition.

Forward Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate. Future events and results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Investor Relations & Financial Media

Integrity Media Inc.

[email protected]

Toll Free: (888) 216-3595

www.IntegrityMedia.com